• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Speeding Up With CAR-T Cell Therapy in Multiple Myeloma

by | Sep 3, 2024 | Uncategorized

Source: CureToday articles CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Read More

Multiple Myeloma Remission: A Glimmer of Hope

by | Aug 30, 2024 | Uncategorized

Source: CureToday articles As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope. Read More

10 Multiple Myeloma Questions and Answers: Treatments and Side Effects

by | Aug 29, 2024 | Uncategorized

Source: CureToday articles Patients with multiple myeloma now have several available treatment options, so it’s important to have answers to some of the frequently asked questions. Read More

The Solitude of Reality With Multiple Myeloma

by | Aug 28, 2024 | Uncategorized

Source: CureToday articles I was diagnosed with stage 1 multiple myeloma in 2018 and writing poetry helped me work through feelings of anger and acceptance. Read More

Multiple Myeloma: 8 Frequently Asked Patient Questions

by | Aug 27, 2024 | Uncategorized

Source: CureToday articles Questions about multiple myeloma regarding treatment options, bone strength and other associated comorbidities were answered by an expert. Read More

My Olympics With Multiple Myeloma

by | Aug 12, 2024 | Uncategorized

Source: CureToday articles After my myeloma diagnosis, each day is my own personal Olympics, filled with trials and triumph. Read More
« Older Entries
Next Entries »

Recent Content

  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
  • VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
  • Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
  • Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
  • Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT